Dr. Robin K. Avery, MD

Dr. Avery practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Avery's NPI, 1740244318, was assigned on April 12, 2006. Dr. Avery graduated from Harvard Medical School in 1985. Dr. Avery holds Maryland license D74450.

Dr. Avery's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Avery's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Avery is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Avery to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Avery practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Avery's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Avery is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Avery's licenses on file in 2 states: Maryland and Ohio.

Dmand AI lists acute skin infection, immune deficiency disease, shingles and UTI among the conditions Dr. Avery treats.

CMS data shows 384 Medicare services from Dr. Avery across 8 procedure codes in 2024, for 154 Medicare patients. Medicare paid $35,404 for them.

CMS counts 154 Medicare patients who saw Dr. Avery in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 4.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Avery's median patient age at 69, with 53% women.

In 2024, Dr. Avery wrote 324 Medicare Part D claims for 57 patients. 92% of them were for generic drugs. CMS names the drug for 218 of them, across 11 drugs with 11 or more claims each, at $4,736 in total drug cost. In 2023, CMS named 259 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Avery for performance year 2024, reported as part of a group. CMS lists Dr. Avery as offering telehealth.

Dmand AI links 237 papers to Dr. Avery, published from 2002 to 2025. 2022 was the busiest year, with 28. The most frequent topics are Transplant Recipients, COVID-19 and Organ Transplantation. Dr. Avery has published most often in Transplantation. Dr. Avery's most frequent co-authors are Dorry Segev, MD, William Adam Werbel, MD and Brian Joel Boyarsky, MD.

Dmand AI links Dr. Avery to 6 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Infections, Herpes Simplex and Skin Diseases, Viral. Shire sponsors the most, 2.

CMS Open Payments shows 5 general payments to Dr. Avery from 3 drug and device companies from 2023 to 2025. Speaker and faculty fees make up the largest share, 97% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $2,877.

Dmand AI lists 3 awards for Dr. Avery, most recently Best Consulting Physician in 2017.

Dr. Avery graduated from Harvard Medical School in 1985. Dr. Avery is a member of American Society of Transplantation, Immunocompromised Host Society, IDSA, International Society for Heart and Lung Transplantation (ISHLT) and SHM.

Dr. Avery is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.